Reliability of plasma fibroblast growth factor 23 as risk biomarker in epidemiological studies measured over a four-month period

Annals of Clinical Biochemistry

Volumn 49, Issue 6, 2012, Pages 542-545

  Di Giuseppe, Romina ^a   Hirche, Frank ^b   Montonen, Jukka ^a   Buijsse, Brian ^a   Dierkes, Jutta ^c   Stangl, Gabriele I ^b   Boeing, Heiner ^a   Weikert, Cornelia ^a,d  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF BERGEN   (Norway)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENCE;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SEX FACTORS;

EID: 84872470774     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2012.011273     Document Type: Article

References (25)

1. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008;118:3820-8
2. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006;291:E38-49
3. Nakai K, Komaba H, Fukagawa M. New insights into the role of fibroblast growth factor 23 in chronic kidney disease. J Nephrol 2010;23:619-25
4. Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) study. J Am Soc Nephrol 2007;18:2600-8
5. Cozzolino M, Mazzaferro S. The fibroblast growth factor 23: a new player in the field of cardiovascular, bone and renal disease. Curr Vasc Pharmacol 2010;8:404-11
6. Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010;152:640-8
7. Dalal M, Sun K, Cappola A, et al. Relationship of fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women. Eur J Endocrinol 2011;165:797-803
8. Gutierrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol 2011;6:2871-8
9. Holecki M, Chudek J, Wiecek A, Titz-Bober M, Dulawa J. The serum level of fibroblast growth factor-23 and calcium-phosphate homeostasis in obese perimenopausal women. Int J Endocrinol 2011;2011:707126
10. Boeing H, Korfmann A, Bergmann MM. Recruitment procedures of EPIC-Germany. European investigation into cancer and nutrition. Ann Nutr Metab 1999;43:205-15
11. Duval V, Karlsson MO. Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model. Pharm Res 2002;19:1835-40
12. Vestergaard S, Nielsen F, Andersson AM, et al. Association between perfluorinated compounds and time to pregnancy in a prospective cohort of Danish couples attempting to conceive. Hum Reprod 2012;27:873-80
13. Rosner B. Fundamentals of Biostatistics. 6th edn. Belmont, CA: Duxbury Press, 2006:613-18
14. Fleiss JLLB, Paik MC. Statistical Methods for Rates and Proportions. 2nd edn. New York: Wiley & Sons, 1981:212-36
15. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10
16. Pischon T, Hotamisligil GS, Rimm EB. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem 2003;49:650-2
17. Rosner B, Willett WC, Spiegelman D. Correction of logistic regression relative risk estimates and confidence intervals for systematic within-person measurement error. Stat Med 1989;8:1051-69; discussion 1071-3
18. Platz EA, Sutcliffe S, De Marzo AM, et al. Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies. Cancer Causes Control 2010;21:847-51
19. Weikert C, Westphal S, Luley C, Willich SN, Boeing H, Pischon T. Within-subject variation of plasma resistin levels over a 1-year period. Clin Chem Lab Med 2007;45:899-902
20. Rosner B, Spiegelman D, Willett WC. Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. Am J Epidemiol 1992;136:1400-13
21. Michaud DS, Manson JE, Spiegelman D, et al. Reproducibility of plasma and urinary sex hormone levels in premenopausal women over a one-year period. Cancer Epidemiol Biomarkers Prev 1999;8:1059-64
22. Heijboer AC, Levitus M, Vervloet MG, et al. Determination of fibroblast growth factor 23. Ann Clin Biochem 2009;46:338-40
23. Liu P, Bai X, Wang H, Karaplis A, Goltzman D, Miao D. Hypophosphatemia-mediated hypotension in transgenic mice overexpressing human FGF-23. Am J Physiol Heart Circ Physiol 2009;297:H1514-20
24. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003;64:2272-9
25. Nishida Y, Taketani Y, Yamanaka-Okumura H, et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 2006;70:2141-7